Immunomodulation by targeted anticancer agents

Giulia Petroni; Aitziber Buqué; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1016/j.ccell.2020.11.009

Immunomodulation by targeted anticancer agents

Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

151 Citations (Scopus)

Résumé

At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

langue originale	Anglais
Pages (de - à)	310-345
Nombre de pages	36
journal	Cancer Cell
Volume	39
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.ccell.2020.11.009
état	Publié - 8 mars 2021

Accès au document

10.1016/j.ccell.2020.11.009

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3c28bb60df784704bfd93b5e2d34e355,

title = "Immunomodulation by targeted anticancer agents",

abstract = "At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.",

keywords = "BRAF, CD8 cytotoxic T lymphocytes, CDK4/CDK6, CGAS signaling, DNA damage response, EGFR, KRAS, T cells, TGF-β, immune checkpoint blockers, immunogenic cell death",

author = "Giulia Petroni and Aitziber Buqu{\'e} and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2021",

month = mar,

day = "8",

doi = "10.1016/j.ccell.2020.11.009",

language = "English",

volume = "39",

pages = "310--345",

journal = "Cancer Cell",

issn = "1535-6108",

number = "3",

}

TY - JOUR

T1 - Immunomodulation by targeted anticancer agents

AU - Petroni, Giulia

AU - Buqué, Aitziber

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2021/3/8

Y1 - 2021/3/8

N2 - At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

AB - At odds with conventional chemotherapeutics, targeted anticancer agents are designed to inhibit precise molecular alterations that support oncogenesis or tumor progression. Despite such an elevated degree of molecular specificity, many clinically employed and experimental targeted anticancer agents also mediate immunostimulatory or immunosuppressive effects that (at least in some settings) influence therapeutic efficacy. Here, we discuss the main immunomodulatory effects of targeted anticancer agents and explore potential avenues to harness them in support of superior clinical efficacy.

KW - BRAF

KW - CD8 cytotoxic T lymphocytes

KW - CDK4/CDK6

KW - CGAS signaling

KW - DNA damage response

KW - EGFR

KW - KRAS

KW - T cells

KW - TGF-β

KW - immune checkpoint blockers

KW - immunogenic cell death

UR - http://www.scopus.com/inward/record.url?scp=85099254821&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.11.009

DO - 10.1016/j.ccell.2020.11.009

M3 - Review article

C2 - 33338426

AN - SCOPUS:85099254821

SN - 1535-6108

VL - 39

SP - 310

EP - 345

JO - Cancer Cell

JF - Cancer Cell

IS - 3

ER -